Short answer
Sionna Therapeutics, Inc. (SION) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 2.05 (Costs Associated with Exit or Disposal Activities), Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Workforce reduction of approximately 46% to prioritize SION-451 and SION-2222 dual combination program.
Sionna Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.05 · Costs Associated with Exit or Disposal Activities
- Workforce reduction of approximately 46% to prioritize SION-451 and SION-2222 dual combination program
- SION-719 add-on program wind-down, including clinical, manufacturing, and vendor contract terminations
- Estimated restructuring charges of approximately $6.4 million, including $5.3 million severance
- Additional charges include $0.7 million contract close-outs and $0.4 million stock-based compensation
- Implementation expected by end of Q3 2026, with cash payments continuing into Q4 2026
Item 5.02 · Departure/Election of Directors or Officers
- Chief Business Officer Caroline Stark Beer terminated without cause effective September 15, 2026, signaling restructuring-driven leadership consolidation
- CFO Elena Ridloff adds Chief Business Officer duties, while CMO Charlotte McKee adds R&D leadership
- Chief Legal Officer Jennifer Fitzpatrick adds Program Management responsibilities, with no compensation changes
- Employee options above $18.00 repriced to Nasdaq closing price on September 17, 2026, improving retention incentives
- Repriced options retain original exercise prices if exercised before the 18-month retention period ends
Item 8.01 · Other Events
- Phase 2a proof-of-concept trial planned for SION-451 and SION-2222 dual combination program
- Advancement creates a clinical catalyst but carries trial-design, safety, efficacy, and regulatory execution risk
- Corporate update includes restructuring and cost-saving measures intended to preserve cash and extend runway
- Workforce reductions may impair operations and retention of personnel needed for clinical development
- Investors should review Exhibit 99.1 for trial timing, restructuring details, and cash-runway expectations
Item EX-99.1 · Exhibit EX-99.1
- Sionna advancing SION-451 + SION-2222 into Phase 2a, with trial initiation targeted for Q1 2027
- Post hoc analysis showed placebo-adjusted sweat chloride reduction of -8.6 mmol/L after excluding three PK outliers
- SION-719 discontinued as Trikafta add-on after primary analysis showed only -1.0 mmol/L placebo-adjusted reduction
- Workforce reduction of approximately 46% and $6.4M restructuring charges prioritize the dual-combination program
- Cash, equivalents, and marketable securities totaled approximately $268.3M at Q2 2026, with runway projected into second half of 2029
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sionna Therapeutics, Inc. 8-K filings
Get the next SION 8-K as it lands
Follow SION for push alerts, or ask the research agent what this filing means.